Grand Strand Clinical Trial Services, LLC’s Post

Check out the most recent article from our partner, Amicus Therapeutics ! Explore Fabry disease's complexities and dive into its depths. Read the article here: https://lnkd.in/g4HRuanr

Impact of Antihypertensives and CYP3A5*3 Polymorphism in Chronic Kidney Disease Patients Explore the intricate link between antihypertensives and CYP3A5*3 polymorphism in chronic kidney disease. Gain insights for personalized treatment approaches in our informative guide. Learn More: https://lnkd.in/gQzqdj3C

September is National #SickleCellAwarenessMonth. According to the Centers for Disease Control and Prevention (CDC), sickle cell disease (SCD) affects around 100,000 people in the US. Two groundbreaking #genetherapies have been approved by the US Food and Drug Administration (FDA) to treat SCD: Casgevy® (exagamglogene autotemcel), from Vertex Pharmaceuticals and CRISPR Therapeutics, and Lyfgenia™ (lovotibeglogene autotemcel) from bluebird bio. These treatments offer new hope for those living with SCD. To learn more about these costly treatments and to understand your risk, reach out to ETS at 877.445.482 or visit us at https://bit.ly/4dQuTk3. #SickleCellMatters2024. Sickle Cell Disease Association of America: https://bit.ly/47cUDou

💡Did you know, in the past 5 years, we have supported >350 rare disease clinical trials & consulting projects? Download our fact sheet to learn more about how we can help you advance development and approval of rare/ultra-rare disease therapies 📩 https://bit.ly/3IY5yaj #RareDisease #UltraRareDiseases

A new gene-silencing tool shows promise as a future therapy against prion diseases and paves the way for new approaches to treating disease. | Click below to read the full article on Sunalei

February 29 is a rare day; fittingly, it's also Rare Diseases Day.    And while the term 'Rare Disease Day' may evoke a sense of rarity, the reality is - over 300 million people worldwide live with one.    So today, we’re showing our support by featuring our portfolio companies working to improve the well-being and life expectancy of those living with ‘Rare Diseases’.   Certa Therapeutics lead candidate, FT011, holds promise as the first anti-fibrotic and disease-modifying treatment for scleroderma patients. Scleroderma, the most fatal of all rheumatologic diseases, affects approximately 125,000 individuals in the United States alone, with an annual incidence rate of 30 cases per million.   #Respirion Pharmaceuticals is pioneering an inhaled antibiotic combination treatment for cystic fibrosis (CF) patients. This innovative approach aims to provide superior anti-infective performance while enhancing lung function for CF patients of all ages and stages. Cystic fibrosis, a progressive genetic disease, impacts close to 40,000 individuals in the United States, spanning all racial and ethnic groups.   #RareDiseaseDay #CertaTherapeutics #Respirion #Scleroderma #CysticFibrosis #RareDiseaseAwareness"

This article explores the challenges and the necessary solutions to advance rare disease drug development in today’s dynamic landscape. Read it now: https://ow.ly/wibn50RAUsN.

For decades, steroids have been considered a necessary evil to control ANCA-associated vasculitis. Yet today, more patients die from complications associated with glucocorticoid treatment than the underlying disease. Get a summary of the most comprehensive picture to date of evolving diagnostic and therapeutic strategies for this rare but devastating #AutoimmuneDisorder: https://hubs.li/Q02rhSdw0 #Vasculitis #AutoimmuneDiseaseManagement #SteritasGTI #SteroidToxicity #SteroidToxicityAwareness #VasculitisTreatment #SteroidInducedComplications

Despite increasing access to new therapies to treat IBD, a paper presented at #ECCO24 tells a story of continued clinical reliance on steroids to control #IBD disease activity. Explore through this explanation of the study presented, the impact increased steroid usage is having on the #IBDCommunity: https://hubs.li/Q02FV0S20 European Federation of Crohn's and Ulcerative Colitis Associations #EFCCA #SteroidToxicity #SteritasGTI

🚀 Continuing Your Pharma Education: Intestinal Diseases – From Inflammatory Conditions to Intestinal Cancer 🩺 In our latest article, we explore intestinal diseases like IBS, IBD, and intestinal cancer, discussing causes, symptoms, and modern treatment approaches. Learn about the latest pharmaceutical strategies for managing these complex conditions. #IntestinalDiseases #IBD #CeliacDisease #PharmaEducation #IntestinalCancer #GutHealth #NewToPharma #PharmaceuticalIndustry #Gastroenterology #MedicalRepresentative #PharmaColleagues #Health #MedicalStudent #HealthTips Read the full article now and stay tuned for more! 👇 https://lnkd.in/dD4f2cEw